Skip to the content
Please enable JavaScript in your browser to complete this form.
Pre-meeting Survey
Name:
*
1. How many patients with HR-positive/HER2-negative metastatic breast cancer does your institution/hospital manage monthly?
*
<5
5–10
10–20
>20
2. Which first-line treatment regimens are preferentially considered in your hospital/institution for HR-positive/HER2-negative metastatic breast cancer patients not at risk of visceral crisis?
*
(Please list the top 3 options in order of preference and state the reasons for considering each regimen selected)
2. Which first-line treatment regimens are preferentially considered in your hospital/institution for HR-positive/HER2-negative metastatic breast cancer patients not at risk of visceral crisis?
*
3. Among your patients with HR-positive/HER2-negative metastatic breast cancer, what proportion are treated with CDK4/6 inhibitor-based regimen in the first-line setting?
*
0%–25%
26%–50%
51%–75%
76%–100%
4. What proportion of your HR-positive/HER2-negative metastatic breast cancer patients have disease-free interval (DFI) >12 months (are endocrine sensitive)?
*
<40%
40%–60%
61%–80%
>80%
5. Which guideline(s) do you follow when deciding on management for HR-positive/HER2-negative metastatic breast cancer patients?
*
(Select all that apply)
5. Which guideline(s) do you follow when deciding on management for HR-positive/HER2-negative metastatic breast cancer patients? (Select all that apply)
*
National guidelines
Hospital guidelines
International guidelines (i.e., NCCN, ESMO, ASCO, etc.)
Personal experience
Other
Other, please specify :
*
Submit